Do analysts rate VRPX or ADTX?

Given Virpax Pharmaceuticals' higher probable upside, equities research analysts plainly believe Virpax Pharmaceuticals is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ADTX or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, ADTX or BPTH?

Bio-Path has lower revenue, but higher earnings than Aditxt. Bio-Path is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.26 -$41.71M -$100.79 thousand N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is ADTX or BPTH more profitable?

Bio-Path has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Bio-Path N/A -2,842.40% -337.48%

Do analysts prefer SYRS or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SYRS or ADTX?

Aditxt has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syros Pharmaceuticals $386K 0.03 -$164.57M -$3.03 N/A Aditxt $14.34K 0.26 -$41.71M -$100.79 thousand N/A

Do analysts recommend ADTX or TRVN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trevena 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, ADTX or TRVN?

Trevena has higher revenue and earnings than Aditxt. Trevena is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.26 -$41.71M -$100.79 thousand N/A Trevena $443K 0.02 -$40.29M -$47.04 N/A

Is ADTX or TRVN more profitable?

Trevena has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Trevena's return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Trevena N/A N/A -119.55%

Does the media favor ADTX or TRVN?

In the previous week, Aditxt had 1 more articles in the media than Trevena. MarketBeat recorded 2 mentions for Aditxt and 1 mentions for Trevena. Trevena's average media sentiment score of 0.37 beat Aditxt's score of -0.51 indicating that Trevena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aditxt 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Trevena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADTX or NAVB?

Given Navidea Biopharmaceuticals' higher probable upside, analysts plainly believe Navidea Biopharmaceuticals is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Aditxt (ADTX) Competitors

$0.0045 0.00 (-2.17%)

As of 03:59 PM Eastern

Compare

ADTX vs. VRPX, BPTH, SYRS, TRVN, and NAVB

Should you buy Aditxt stock or one of its competitors? Aditxt's main competitors and comparable companies include Virpax Pharmaceuticals (VRPX), Bio-Path (BPTH), Syros Pharmaceuticals (SYRS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aditxt compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Virpax Pharmaceuticals has higher earnings, but lower revenue than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Aditxt	$14.34K	0.26	-$41.71M	-$100.79 thousand	N/A

In the previous week, Aditxt had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.00 beat Aditxt's score of -0.51 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Aditxt	Negative

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Virpax Pharmaceuticals has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Virpax Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Aditxt	-360,152.50%	-374.60%	-105.93%

Given Virpax Pharmaceuticals' higher probable upside, equities research analysts plainly believe Virpax Pharmaceuticals is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virpax Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Virpax Pharmaceuticals and Aditxt tied by winning 7 of the 14 factors compared between the two stocks.

How does Aditxt compare to Bio-Path?

Aditxt (NASDAQ:ADTX) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Aditxt had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 beat Aditxt's score of -0.51 indicating that Bio-Path is being referred to more favorably in the news media.

Company	Overall Sentiment
Aditxt	Negative
Bio-Path	Neutral

15.5% of Aditxt shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aditxt has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market.

Bio-Path has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Bio-Path	N/A	-2,842.40%	-337.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bio-Path has lower revenue, but higher earnings than Aditxt. Bio-Path is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.26	-$41.71M	-$100.79 thousand	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Summary

Aditxt beats Bio-Path on 8 of the 13 factors compared between the two stocks.

How does Aditxt compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aditxt had 2 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Syros Pharmaceuticals. Syros Pharmaceuticals' average media sentiment score of 0.00 beat Aditxt's score of -0.51 indicating that Syros Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Aditxt	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aditxt has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A
Aditxt	$14.34K	0.26	-$41.71M	-$100.79 thousand	N/A

Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Syros Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Aditxt	-360,152.50%	-374.60%	-105.93%

Summary

Syros Pharmaceuticals beats Aditxt on 8 of the 14 factors compared between the two stocks.

How does Aditxt compare to Trevena?

Aditxt (NASDAQ:ADTX) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trevena	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aditxt had 1 more articles in the media than Trevena. MarketBeat recorded 2 mentions for Aditxt and 1 mentions for Trevena. Trevena's average media sentiment score of 0.37 beat Aditxt's score of -0.51 indicating that Trevena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aditxt	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Trevena	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aditxt has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Trevena has a beta of -0.55, indicating that its stock price is 155% less volatile than the broader market.

Trevena has higher revenue and earnings than Aditxt. Trevena is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.26	-$41.71M	-$100.79 thousand	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Trevena has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Trevena's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Trevena	N/A	N/A	-119.55%

Summary

Aditxt and Trevena tied by winning 7 of the 14 factors compared between the two stocks.

How does Aditxt compare to Navidea Biopharmaceuticals?

Aditxt (NASDAQ:ADTX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Given Navidea Biopharmaceuticals' higher probable upside, analysts plainly believe Navidea Biopharmaceuticals is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Navidea Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.26	-$41.71M	-$100.79 thousand	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

In the previous week, Aditxt had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 beat Aditxt's score of -0.51 indicating that Navidea Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aditxt	Negative
Navidea Biopharmaceuticals	Neutral

Aditxt has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Navidea Biopharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Navidea Biopharmaceuticals	N/A	N/A	N/A

Summary

Navidea Biopharmaceuticals beats Aditxt on 9 of the 14 factors compared between the two stocks.

Get Aditxt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADTX vs. The Competition

Export

Metric	Aditxt	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4K	$12.53B	$7.26B	$13.10B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	0.00	792.39	274.98	25.77
Price / Sales	0.26	850.84	679.25	97.61
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.00	10.69	10.52	6.34
Net Income	-$41.71M	$2.83B	$3.49B	$360.00M
7 Day Performance	N/A	-0.69%	-1.08%	-0.11%
1 Month Performance	N/A	-1.10%	-3.39%	-3.42%
1 Year Performance	N/A	2.10%	15.08%	5.46%

Aditxt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADTX Aditxt	0.1508 of 5 stars	$0.00 -2.2%	N/A	-100.0%	$4K	$14.34K	N/A	60	News Coverage
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	$14K	N/A	N/A	2
BPTH Bio-Path	N/A	$0.00 flat	N/A	-99.2%	$11K	N/A	N/A	10
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	+300.0%	$11K	$386K	N/A	68	News Coverage Gap Down
TRVN Trevena	N/A	$0.01 flat	N/A	+12.0%	$11K	$443K	N/A	23	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADTX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aditxt (ADTX) Competitors

ADTX vs. VRPX, BPTH, SYRS, TRVN, and NAVB

How does Aditxt compare to Virpax Pharmaceuticals?

Summary

How does Aditxt compare to Bio-Path?

Summary

How does Aditxt compare to Syros Pharmaceuticals?

Summary

How does Aditxt compare to Trevena?

Summary

How does Aditxt compare to Navidea Biopharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aditxt (ADTX) Competitors

ADTX vs. VRPX, BPTH, SYRS, TRVN, and NAVB

How does Aditxt compare to Virpax Pharmaceuticals?

Which has stronger valuation and earnings, VRPX or ADTX?

Does the media favor VRPX or ADTX?

Do institutionals and insiders believe in VRPX or ADTX?

Which has more risk & volatility, VRPX or ADTX?

Is VRPX or ADTX more profitable?

Do analysts rate VRPX or ADTX?

Summary

How does Aditxt compare to Bio-Path?

Does the media refer more to ADTX or BPTH?

Do institutionals & insiders believe in ADTX or BPTH?

Which has more risk & volatility, ADTX or BPTH?

Is ADTX or BPTH more profitable?

Do analysts prefer ADTX or BPTH?

Which has higher earnings and valuation, ADTX or BPTH?

Summary

How does Aditxt compare to Syros Pharmaceuticals?

Do institutionals and insiders have more ownership in SYRS or ADTX?

Does the media prefer SYRS or ADTX?

Do analysts prefer SYRS or ADTX?

Which has higher valuation & earnings, SYRS or ADTX?

Which has more risk and volatility, SYRS or ADTX?

Is SYRS or ADTX more profitable?

Summary

How does Aditxt compare to Trevena?

Do institutionals & insiders hold more shares of ADTX or TRVN?

Do analysts recommend ADTX or TRVN?

Does the media favor ADTX or TRVN?

Which has more volatility & risk, ADTX or TRVN?

Which has stronger valuation & earnings, ADTX or TRVN?

Is ADTX or TRVN more profitable?

Summary

How does Aditxt compare to Navidea Biopharmaceuticals?

Do analysts rate ADTX or NAVB?

Which has stronger valuation & earnings, ADTX or NAVB?

Does the media favor ADTX or NAVB?

Which has more risk & volatility, ADTX or NAVB?

Do insiders & institutionals believe in ADTX or NAVB?

Is ADTX or NAVB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools